Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss, KK Burkhart… - BMC …, 2020 - Springer
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse
events. We developed a preliminary approach to predict 135 adverse events using post-
market safety data from marketed drugs. Adverse event information available from FDA
product labels and scientific literature for drugs that have the same activity at one or more of
the same targets, structural and target similarities, and the duration of post market …
events, often these trials are not sufficiently powered to detect difficult to observe adverse
events. We developed a preliminary approach to predict 135 adverse events using post-
market safety data from marketed drugs. Adverse event information available from FDA
product labels and scientific literature for drugs that have the same activity at one or more of
the same targets, structural and target similarities, and the duration of post market …
Predicting potential adverse events using safety data from marketed drugs
R Racz - 2020 - kilthub.cmu.edu
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse
events. We developed a preliminary approach to predict 135 adverse events using post-
market safety data from marketed drugs. Adverse event information available from FDA
product labels and scientific literature for drugs that have the same activity at one or more of
the same targets, structural and target similarities, and the duration of post market …
events, often these trials are not sufficiently powered to detect difficult to observe adverse
events. We developed a preliminary approach to predict 135 adverse events using post-
market safety data from marketed drugs. Adverse event information available from FDA
product labels and scientific literature for drugs that have the same activity at one or more of
the same targets, structural and target similarities, and the duration of post market …
Showing the best results for this search. See all results